ERBB2 and gastric cancer: Recently, anti-ErbB2 antibody–drug conjugates, such as trastuzumab, were approved for ErbB2-positive gastric cancers, and the addition of trastuzumab to first-line chemotherapy has improved the overall survival of ErbB2-positive gastric cancer patients, becoming the standard-of-care treatment for this group of patients [19,20].